Exact Sciences to present new positive data on Oncodetect in colorectal cancer

Exact Sciences (EXAS) announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease – MRD – test, Oncodetect, in predicting recurrence in stage II-IV colorectal cancer. These data confirm the test’s role in supporting treatment and surveillance decisions. Exact Sciences will introduce a next-generation version of the test leveraging the Broad Institute’s MAESTRO technology. Early data show the test will track up 5,0002 patient specific variants and detect ctDNA levels below 1 part per million. The test will be available to both new and existing customers in 2026. Data from the Beta-CORRECT clinical validation study confirm that the Oncodetect test accurately predicts recurrence in stage III colorectal cancer-consistent with findings from the Alpha-CORRECT study-and extends this association to stages II and IV. Those with ctDNA-positive results after therapy and during surveillance showed a 24- and 37-fold increased risk of recurrence, respectively. The next-generation MRD test, currently in validation across multiple solid tumor types, will track up to 5,000 patient-specific variants with a limit of detection below 1 part per million.